Titre :

Impact of the Beta-Glucan Test on Management of Intensive Care Unit Patients at Risk for Invasive Candidiasis

Auteur(s) :

Kritikos, Antonios [Auteur]

Poissy, Julien [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Croxatto, Antony [Auteur]

Bochud, Pierre-Yves [Auteur]

Pagani, Jean-Luc [Auteur]

Lamoth, Frederic [Auteur]

Titre de la revue :

Journal of clinical microbiology

Nom court de la revue :

J Clin Microbiol

Numéro :

58

Éditeur :

American Society for Microbiology

Date de publication :

2020-05-26

ISSN :

1098-660X

Mot(s)-clé(s) en anglais :

antifungal therapy
beta-glucan
candidemia
intra-abdominal candidiasis

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

The 1,3-beta- d -glucan (BDG) test is used for the diagnosis of invasive candidiasis (IC) in intensive care units (ICUs). However, its utility for patient management is unclear. This study assessed ...
Lire la suite >The 1,3-beta- d -glucan (BDG) test is used for the diagnosis of invasive candidiasis (IC) in intensive care units (ICUs). However, its utility for patient management is unclear. This study assessed the impact of BDG test results on therapeutic decisions. This was a single-center observational study conducted in an ICU over two 6-month periods. All BDG test requests for the diagnosis of IC were analyzed. Before the second period, the ICU physicians received a pocket card instruction (algorithm) for targeted BDG testing in high-risk patients.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CNRS

Collections :

• Autres travaux scientifiques

Équipe(s) de recherche :

Glycobiology in fungal Pathogenesis and Clinical Applications

Date de dépôt :

2021-07-15T07:58:43Z
2021-07-16T12:09:16Z